Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 2257635

Absorption enhancers.

S Muranishi
View original source ↗Export metadata ↓

Abstract

Many current therapeutic drugs, e.g., antibiotics and peptide drugs, are impermeable to outer tissue barriers. Drug delivery of impermeable drugs through such barriers is currently one of the major interests in pharmaceutical research. New classes of absorption enhancers provide rapid absorption in the gastrointestinal tract or skin, with no side effects. This review covers the history of enhancer research, an overview of a variety of absorption enhancers, the nature of enhancing action, and site specificity. The final section focuses on the mechanisms of enhancer action which transiently abolishes or reverses barrier resistance, from the viewpoints of the lipid bilayer barrier containing SH proteins, as well as transcellular/paracellular pathways. Fully understanding these mechanisms is of importance for therapeutic applications.

Explore related subjects

Adjuvants, PharmaceuticAnimalsCell Membrane PermeabilityHumansIntestinal AbsorptionSkin AbsorptionStructure-Activity RelationshipJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Muranishi. 1990. Absorption enhancers.. https://pubmed.ncbi.nlm.nih.gov/2257635/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Quinoxaline antibiotics enhance peptide nucleic acid binding to double-stranded DNA.

The effects of a wide range of DNA binding drugs on peptide nucleic acid (PNA) binding to double-stranded DNA by strand displacement have been investigated using a gel retardation assay. The bis-PNA [H-(Lys)-TTJTTJTTTT-(eg)(3)-TTTTCTTCTT-Lys-NH(2)] was used together with a 248 bp DNA fragment containing an appropriate target for the PNA. Most of the ligands that were studied, including DNA minor groove binders as well as intercalators and bis-intercalators, either have no effect or strongly inhibit PNA binding to DNA. By contrast, quinoxaline antibiotics facilitate PNA-DNA complex formation. The "PNA-helper" effect of echinomycin was studied in more detail using time and temperature dependence experiments to elucidate the mechanism. PNA binding to DNA follows pseudo-first-order kinetics, but the initial rate of binding is accelerated more than 10-fold in the presence of 10 microM echinomycin. The activation energy for PNA binding to dsDNA is lowered 2-fold by the antibiotic (45 vs 90 kJ/mol in the control). The reasons why quinoxalines promote the binding of PNA to DNA are not entirely clear but may well include distortions (opening) of the double helix that facilitate PNA invasion. This study establishes that the efficacy of DNA-targeted PNA antigene molecules could potentially be enhanced by judiciously adding certain DNA-interactive ligands.

Adjuvants, Pharmaceutic↗
PubMed2000

Antithrombotic efficacy of single subcutaneous administration of a recombinant nematode anticoagulant peptide (rNAP5) in a canine model of coronary artery thrombolysis.

We examined the adjunctive benefit of recombinant nematode anticoagulant peptide (rNAP5), a factor Xa inhibitor, in a canine model of recombinant (rt)-PA-induced thrombolysis. In anesthetized dogs, a stable occlusive thrombus was formed by electrolytic injury of the vessel wall, after which the animals were administered rt-PA (1.44 mg/kg, i.v.) and rNAP5 (0.1 mg/kg, s.c.: n=13), or rt-PA plus vehicle (1-2 ml, s.c.; n=13). Hemodynamic and coagulation parameters were monitored for 360 minutes. Single subcutaneous administration of rNAP5 resulted in a prolonged and sustained increase in the activated partial thromboplastin time (>100-fold), whereas prothrombin time was unchanged. The template bleeding time was not altered significantly throughout the protocol (maximum 1.4-fold). The incidence of reperfusion was similar in the two groups with a trend toward faster reperfusion in the rNAP5 group (34+/-4 minutes) compared to the vehicle group (63+/-15 minutes; p=0.07). After reperfusion, 80% of the vessels in the vehicle group reoccluded, whereas only 14% of vessels reoccluded in the rNAP5-treated group. Times to reocclusion were 65+/-21 minutes and 221+/-28 minutes, respectively (p<0.05). Single subcutaneous administration of rNAP5 sustained the coronary artery blood flow after reperfusion, such that at the end of protocol the flow was 47% of the preocclusion value as compared to the vehicle group in which the flow was 11% (p<0.05). Cyclic flow reductions were most prominent during rt-PA-induced reperfusion and were similar in both groups. The results indicate that a single subcutaneous administration of rNAP5 provides a sustained antithrombotic effect in maintaining the coronary artery patency during rt-PA-induced thrombolysis.

Adjuvants, Pharmaceutic↗